Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience
| Autor: | C. Da Silva Rodriguez, E. Fernández-Fonseca, J. J. Sánchez Blanco, Tomás José González-López, Rocío Arranz, B. Sánchez González, A. M. Ruedas López, Jimena Cannata-Ortiz, R. Oña Navarrete, Sonia Maciá, M. J. Ramírez Sánchez, P. Martínez Barranco, Eva Domingo-Domenech, C. Martínez Chamorro, Concepción Nicolás, B. Navarro Matilla, Rufina Pérez, Carlos Panizo, Ana García-Noblejas |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male Bendamustine medicine.medical_specialty Population Salvage therapy Lymphoma Mantle-Cell Gastroenterology Recurrence Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Bendamustine Hydrochloride Humans Treatment Failure education Aged Retrospective Studies Aged 80 and over Salvage Therapy education.field_of_study Performance status business.industry Hematology General Medicine Middle Aged medicine.disease Surgery Regimen Drug Resistance Neoplasm Spain Nitrogen Mustard Compounds Female Mantle cell lymphoma Rituximab business Febrile neutropenia medicine.drug |
| Zdroj: | Annals of Hematology. 93:1551-1558 |
| ISSN: | 1432-0584 0939-5555 |
| DOI: | 10.1007/s00277-014-2077-1 |
| Popis: | Patients with mantle cell lymphoma (MCL) have an adverse outcome after relapse. Bendamustine has demonstrated a good efficacy and toxicity profile in previously reported trials. In this study, we present a retrospective analysis of the Spanish experience in relapsed/refractory MCL treated with bendamustine in combination or alone with the objective of knowing the efficacy and toxicity profile of this treatment in our current clinical practice. Fifty eight patients were registered: 67 % male with median age of 71 years, and 2 is the median number of previous lines. The most frequent bendamustine regimen was bendamustine plus rituximab (83 %). The median number of cycles was 5 (range 1–8). The overall response rate was 84 % with 53 % of complete response/unconfirmed complete response (CR/uCR). Median progression-free survival (PFS) was 16 months (95 % confidence interval (CI) 13.3–18.8), and for patients who achieved CR/uCR, it was 33 months (95 % CI 11.1–54.2). Median overall survival (OS) was 30 months (95 % CI 25.6–34.9). For PFS, only blastoid histology and not achieving CR after bendamustine had a significant negative impact on the univariate and multivariate analyses (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink